Compare NHTC & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHTC | ITRM |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 24.3M |
| IPO Year | 1999 | 2018 |
| Metric | NHTC | ITRM |
|---|---|---|
| Price | $2.02 | $0.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 25.8K | ★ 30.9M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 13.51% | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,776,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.25 | $0.03 |
| 52 Week High | $5.10 | $1.13 |
| Indicator | NHTC | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 24.04 | 26.10 |
| Support Level | N/A | N/A |
| Resistance Level | $3.32 | $0.39 |
| Average True Range (ATR) | 0.16 | 0.02 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 2.23 | 3.34 |
Natural Health Trends Corp is an international direct-selling and e-commerce company. It offers a line of products such as Wellness, Herbal, Beauty, Lifestyle, and Home. Wellness products include targeted nutrition for joint health, antioxidant support, digestive health, heart health, and vision health. Herbal products include anti-aging and hydrating cleansers, creams, lotions, serums, and toners. Lifestyle products improve the overall quality of life and support active, physical, and healthy lifestyles. Home products are designed to create a clean and natural living environment for the home. It generates a majority of its revenue from Hong Kong and the rest from China, Taiwan, Japan, the United States, and other regions.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.